{"title":"Effects of <sup>131</sup>I and TSH suppression therapy on METTL3, METTL14 levels and recurrence in thyroid cancer.","authors":"Li-Guo Yang, Zhi-Gang Yang, Jun Zhang, Yi-Li Fu","doi":"10.62347/THJB4749","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study aims to evaluate the changes in the expression levels of METTL3 and METTL14 in patients with differentiated thyroid cancer (DTC) and their association with thyroid function indicators, as well as to explore the potential value of these genes in predicting the risk of DTC recurrence.</p><p><strong>Methods: </strong>This cohort study included 189 DTC patients treated at Shidong Hospital between April 2016 and February 2021. Patients were divided into an experimental group, which received combined radioactive iodine (<sup>131</sup>I) therapy and thyroid-stimulating hormone (TSH) suppression therapy (n = 119), and a control group, which received only TSH suppression therapy (n = 70). Messenger RNA (mRNA) expression levels of METTL3 and METTL14 in patients' serum were measured before and six months after treatment using quantitative real-time polymerase chain reaction (qRT-PCR). Thyroid function indicators, including free triiodothyronine (FT3), free thyroxine (FT4), TSH, and thyroglobulin (Tg), were assessed using electrochemiluminescence immunoassay. Disease-free survival (DFS) was analyzed using Cox regression analysis, and data visualization was performed with the ggplot2 package in R.</p><p><strong>Results: </strong>Both METTL3 and METTL14 expression levels significantly decreased after treatment in both the experimental and control groups (P < 0.001). Regarding thyroid function indicators, FT3 and FT4 levels significantly increased, while TSH and Tg levels significantly decreased post-treatment (P < 0.001). Lower post-treatment expression levels of METTL3 and METTL14 were significantly associated with a higher risk of recurrence. Cox regression analysis further indicated that post-treatment METTL3, METTL14, TSH, and Tg levels were independent predictors of DFS (P < 0.05).</p><p><strong>Conclusion: </strong>Low expression levels of METTL3 and METTL14 are closely associated with malignant progression and an increased risk of recurrence in DTC. Patients receiving combined <sup>131</sup>I and TSH suppression therapy demonstrated longer DFS. These findings suggest that METTL3 and METTL14 could serve as potential biomarkers for prognosis evaluation in DTC patients.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 1","pages":"42-58"},"PeriodicalIF":3.6000,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11815380/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.62347/THJB4749","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: This study aims to evaluate the changes in the expression levels of METTL3 and METTL14 in patients with differentiated thyroid cancer (DTC) and their association with thyroid function indicators, as well as to explore the potential value of these genes in predicting the risk of DTC recurrence.
Methods: This cohort study included 189 DTC patients treated at Shidong Hospital between April 2016 and February 2021. Patients were divided into an experimental group, which received combined radioactive iodine (131I) therapy and thyroid-stimulating hormone (TSH) suppression therapy (n = 119), and a control group, which received only TSH suppression therapy (n = 70). Messenger RNA (mRNA) expression levels of METTL3 and METTL14 in patients' serum were measured before and six months after treatment using quantitative real-time polymerase chain reaction (qRT-PCR). Thyroid function indicators, including free triiodothyronine (FT3), free thyroxine (FT4), TSH, and thyroglobulin (Tg), were assessed using electrochemiluminescence immunoassay. Disease-free survival (DFS) was analyzed using Cox regression analysis, and data visualization was performed with the ggplot2 package in R.
Results: Both METTL3 and METTL14 expression levels significantly decreased after treatment in both the experimental and control groups (P < 0.001). Regarding thyroid function indicators, FT3 and FT4 levels significantly increased, while TSH and Tg levels significantly decreased post-treatment (P < 0.001). Lower post-treatment expression levels of METTL3 and METTL14 were significantly associated with a higher risk of recurrence. Cox regression analysis further indicated that post-treatment METTL3, METTL14, TSH, and Tg levels were independent predictors of DFS (P < 0.05).
Conclusion: Low expression levels of METTL3 and METTL14 are closely associated with malignant progression and an increased risk of recurrence in DTC. Patients receiving combined 131I and TSH suppression therapy demonstrated longer DFS. These findings suggest that METTL3 and METTL14 could serve as potential biomarkers for prognosis evaluation in DTC patients.
期刊介绍：
The American Journal of Cancer Research (AJCR) (ISSN 2156-6976), is an independent open access, online only journal to facilitate rapid dissemination of novel discoveries in basic science and treatment of cancer. It was founded by a group of scientists for cancer research and clinical academic oncologists from around the world, who are devoted to the promotion and advancement of our understanding of the cancer and its treatment. The scope of AJCR is intended to encompass that of multi-disciplinary researchers from any scientific discipline where the primary focus of the research is to increase and integrate knowledge about etiology and molecular mechanisms of carcinogenesis with the ultimate aim of advancing the cure and prevention of this increasingly devastating disease. To achieve these aims AJCR will publish review articles, original articles and new techniques in cancer research and therapy. It will also publish hypothesis, case reports and letter to the editor. Unlike most other open access online journals, AJCR will keep most of the traditional features of paper print that we are all familiar with, such as continuous volume, issue numbers, as well as continuous page numbers to retain our comfortable familiarity towards an academic journal.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
